Visit your local Alkaloid website

Alkaloid AD’s groundbreaking formulation of ready-to-use liquid Omeprazole, a value-added drug representing the world’s first of its kind, has been awarded the 2023 Patent of the Year by the State Office of Industrial Property. This recognition was revealed during the celebrations commemorating World Intellectual Property Day on April 26th.

Alkaloid submitted its international patent application for liquid Omeprazole on April 17, 2020, covering numerous regions and countries including the EU countries, the United States, Canada, China, and the Eurasian Economic Union countries, among others. The patent application submitted to the European Patent Office, which oversees patent activities across 39 European countries, was granted approval on August 3 of the previous year and was validated in approximately thirty countries, including Macedonia.

Alkaloid AD’s patent protects a liquid pharmaceutical dosage form of Omeprazole based on enclosing two separate solutions in a dual-chamber package, which upon opening automatically mixes these solutions to provide ready-to-use liquid Omeprazole. This preparation is primarily designed to treat reflux esophagitis and gastroesophageal reflux disease (GERD) in young children unable to swallow tablets, as well as in adult patients who have difficulty swallowing (dysphagia patients) and those with an inability to swallow (gastric feeding tube patients and/or geriatric patients).

The State Office of Industrial Property was established on December 1, 1993, as an autonomous body within the state administration, tasked with managing activities related to obtaining and safeguarding industrial property rights encompassing patents, industrial designs, trademarks and product origin indications. For thirty consecutive years, this institution has been consistently organizing activities focused on promoting the significance of industrial property in fostering innovation and creative endeavors.